The study aims at gathering additional data on the safety and effectiveness of using intravenous administration of the drugs Ca-DTPA/Zn-DTPA to remove the heavy metal gadolinium from the bodies of patients who have retained it and developed symptoms of Gadolinium Deposition Disease following an MRI in which a gadolinium-containing contrast agent was utilized. The outcome data will include measures of symptom relief after as many as six paired Calcium-DTPA/Zinc-DTPA chelation treatments. The study also aims at gathering additional data before and after DTPA treatment regarding levels of certain cytokines in the patients' blood that have been reported to be abnormally elevated in patients with retained gadolinium.

开始日期2023-04-11

申办/合作机构

Stanford University

NCT04138056 / Completed临床2期

A Phase II Study of a Primary Dose of Investigational RSV Maternal Vaccine, Given Alone or With Boostrix, With a 2nd Dose Investigational RSV Maternal Vaccine

The purpose of this study is to evaluate the safety, ability of GSK Biologicals' investigational RSV maternal vaccine (RSVPreF3) to generate an immune response and the degree to which the vaccine can cause side effects, when administered alone and in combination with Boostrix vaccine in healthy non-pregnant women 18-45 years of age. Two dose levels of RSVPreF3 and 2 Boostrix [Diphtheria, Tetanus and acellular Pertussis (dTpa) vaccine] formulations (US and ex-US) will be evaluated. A 2nd dose of RSVPreF3 will be administered in an extension of the study to assess the durability of the immune response after the first dose vaccination, and to assess the safety and immunogenicity following a second dose vaccination of the RSVPreF3 maternal vaccine.

开始日期2019-11-05

申办/合作机构

GSK Plc

NCT02450279 / TerminatedN/A

Scintigraphic Comparison of Lung Deposition With Two Nebulizers During Invasive Mechanical Ventilation

Many devices are available for nebulising drug solution during invasive mechanical ventilation. Vibrating-mesh nebulizers ensure the highest lung deposition output. A recent international survey on aerosol therapy during mechanical ventilation (Ehrmann et al. 2013) reported that jet nebulizers remained the mostly used.
The aim of this study is to compare lung deposition of a radiolabeled administered with both nebulizers during invasive mechanical ventilation by planar scintigraphy.

开始日期2016-03-01

申办/合作机构

Cliniques Universitaires Saint-Luc

100 项与锝[99mTc]喷替酸盐相关的临床结果

登录后查看更多信息

100 项与锝[99mTc]喷替酸盐相关的转化医学

登录后查看更多信息

100 项与锝[99mTc]喷替酸盐相关的专利（医药）

登录后查看更多信息

4,234

项与锝[99mTc]喷替酸盐相关的文献（医药）

2024-03-01·Carbohydrate polymers

Rapid self-healing carboxymethyl chitosan/hyaluronic acid hydrogels with injectable ability for drug delivery

Article

作者: Zhang, Fengjiao ; Feng, Yao ; Cui, Shuyuan ; Coseri, Sergiu ; Jing, Xiaokai ; Zhang, Sufeng

In this study, the quaternized carboxymethyl chitosan (QCMCS), oxidized hyaluronic acid (OHA), 3,3'-dithiobis-(propionohydrazide) (DTP) were used as raw materials for the synthesis of hydrogels with excellent properties as carriers for drug release. The hydrogels were prepared by a simple "one-pot" method without external stimuli on the basis of interactions between formed dynamic covalent bonds (imine bonds, acylhydrazone bonds, disulfide bonds) and hydrogen bonds. The hydrogels had rapid self-healing properties, with a self-healing rate of 96 % after 30 min, as well as good pH responsiveness and excellent cytocompatibility (up to 98 % cell survival). The compressive stress of the hydrogels reached 423 kPa. Moreover, a representative drug (acetylsalicylic acid) demonstrated sustained release in the hydrogels (>72 h). The drug release behaviour was shown to be consistent with the Fick diffusion mechanism by kinetic modelling. Collectively, the findings demonstrate that the QCMCS + OHA + DTP injectable self-healing hydrogels are a potential material for the construction of pH-controlled drug delivery platforms.

2024-03-01·Journal of neurosurgery

Radionuclide shuntography for cerebrospinal fluid shunt flow evaluation in adults

Article

作者: Klein, Jon P ; Alwakeal, Amr ; Avery, Ryan J ; Nandoliya, Khizar R ; Potts, Matthew B ; Linscheid, Logan

OBJECTIVE:

Radionuclide shuntography (RS) performed using 99mTc-DTPA injected into the reservoir of CSF shunts enables evaluation of CSF flow for suspected shunt malfunctions. The goal of this study was to report the authors’ institutional experience with RS and evaluate its utility and associated complications.

METHODS:

The authors retrospectively reviewed all RS studies performed between November 2003 and June 2022. Patients with shunted hydrocephalus who were ≥ 18 years of age were included. Patients undergoing RS for evaluation of Ommaya reservoirs were excluded. Demographics, hydrocephalus etiology, presenting symptoms, study results, subsequent management, complications, and intraoperative diagnoses were recorded. Chi-square tests were reported for categorical variables and standard 2 × 2 contingency methods were used for sensitivity/specificity analysis.

RESULTS:

The authors identified 211 RS procedures performed in 142 patients. The mean age at procedure was 55.6 ± 20.9 years (mean ± SD). Normal pressure hydrocephalus was the most common hydrocephalus etiology (37.0%), followed by congenital malformations (26.1%) and idiopathic intracranial hypertension (15.6%). Successful radionuclide injection was achieved in 207 studies (98.1%). Shunt patency was confirmed in 63.8% of successful injections, whereas malfunction was demonstrated in 27.1% and abnormally slow flow was seen in 9.2%. RS studies demonstrating shunt malfunction were more likely to result in subsequent revisions than were studies showing patency (86.6% vs 2.9%; p < 0.0001). The overall sensitivity and specificity of RS for detecting shunt malfunction was 92.3% and 96.2%, respectively. The median follow-up time was 29 months, with 151 cases having ≥ 6 months of follow-up. There were no complications or infections attributable to RS in this cohort.

CONCLUSIONS:

RS is a useful and safe tool in the workup of shunt malfunction.

2024-02-01·Nuclear medicine communications

A comparative study on the quality of in vivo labeled red blood cell radionuclide ventriculography images employing different freeze-dried reagents

Article

作者: Felix, Renata C. M. ; Guimarães, Tiago T. ; Pujatti, Priscilla B. ; Cardoso, Marcella A. S. ; Gomes, Maria Luisa ; dos Santos, João Paulo G.

Radionuclide ventriculography or Multi Gated Acquisition (MUGA) employing [99mTc]Technetium red blood cell (RBC) labeling is considered the gold standard for cardiotoxicity assessments in cancer patients undergoing chemotherapy. This in-vivo RBC labeling technique involves the reduction of [99mTc]Technetium by the stannous chloride present in freeze-dried reagent kits, with the pyrophosphate kit (PYP) being the most employed for this purpose. The literature, however, describes diethylenetriaminepentaacetic acid (DTPA) as an alternative to PYP, although a lack of comparative data from MUGA images between both reagents is noted. A retrospective cross-sectional observational study was conducted at the Brazilian National Cancer Institute Nuclear Medicine Service concerning 80 randomized MUGA images, 20 obtained employing DTPA between 2020 and 2023 and 60 obtained employing PYP between 2017 and 2020, applying the mean count per pixel (ct/pixel) and heart background (C/F) ratios as quality image indicators. Although the heart ct/pixel ratio was statistically lower in the DTPA images compared with PYP (P = 0.02), the C/F ratio was statistically similar when comparing both radiopharmaceuticals (P = 0.697). A semi-quantitative analysis of MUGA images obtained with DTPA and PYP indicates similar image quality, supporting the use of DTPA as an alternative to PYP without compromising diagnostic interpretations.

项与锝[99mTc]喷替酸盐相关的新闻（医药）

2024-06-11

·PRNewswire

Global Anti-Radiation Drugs Market to Register Incremental Growth at a CAGR of ~9% by 2030 | DelveInsight

The rise in demand for anti-radiation drugs is mainly driven by several factors. These include the growing occurrence of side effects linked to cancer screening methods, heightened risks of exposure to radiological or nuclear emergencies, and the increasing focus of nuclear-capable nations on safeguarding against radiation. These trends are expected to fuel the expansion of the anti-radiation drugs market from 2024 to 2030. LAS VEGAS, June 11, 2024 /PRNewswire/ -- DelveInsight's Anti-Radiation Drugs Market Insights report provides the current and forecast market analysis, individual leading anti-radiation drugs companies' market shares, challenges, anti-radiation drugs market drivers, barriers, trends, and key market anti-radiation drugs companies in the market. Key Takeaways from the Anti-Radiation Drugs Market Report As per DelveInsight estimates, North America is anticipated to dominate the global anti-radiation drugs market during the forecast period. In the compound type segment of the anti-radiation drugs market, the Potassium iodide sub-category had a significant revenue share in the year 2023. This can be ascribed to the various characteristics and advantages associated with potassium iodide. Notable anti-radiation drugs companies such as Novartis AG, Anbex Inc., Amgen Inc., Myelo Therapeutics, Arco Pharmaceuticals LLC, BTG International Inc., Cellphire Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Chrysalis BioTherapeutics Inc., Pluri Inc., Partner Therapeutics, HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG., RxBio Inc., Coherus Biosciences, Onconova Therapeutics, Jubilant Life Sciences, Soligenix Inc., and several others, are currently operating in the anti-radiation drugs market. In September 2023, the U.S. Department of Defense awarded Edina-based Humanetics a USD 20 million contract to develop a pill that prevents radiation damage in military members and first responders affected by events such as nuclear accidents, warfare, and dirty bombs. In May 2023, the first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body, testing the safety, tolerability, and processing in the body of escalating doses of the investigational drug product HOPO 14-1 was initiated in healthy adults. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, was funding the Phase 1 trial, which was sponsored and conducted by SRI International of Menlo Park, California. In March 2022, Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body. These patients have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy). To read more about the latest highlights related to the anti-radiation drugs market, get a snapshot of the key highlights entailed in the Global Anti-Radiation Drugs Market Report Anti-Radiation Drugs Overview Anti-radiation drugs are pharmaceutical compounds designed to mitigate the damaging effects of radiation exposure on the human body. These drugs work by either scavenging free radicals generated by radiation or by enhancing the repair mechanisms of cells damaged by radiation. One class of anti-radiation drugs includes radioprotectors, which are administered before radiation exposure to prevent or reduce its harmful effects. Another class, known as radiomitigators, is given after exposure to alleviate the severity of radiation-induced damage. These drugs hold significant promise in scenarios such as nuclear accidents, medical radiation therapy, and space travel, where the risk of radiation exposure is a concern. Research into anti-radiation drugs is ongoing, with scientists continually striving to improve their efficacy and minimize side effects. Some compounds under investigation show potential not only in protecting against acute radiation sickness but also in mitigating long-term effects such as cancer development. As our understanding of radiation biology advances, coupled with advancements in drug development technologies, the prospects for more effective and accessible anti-radiation drugs continue to brighten, offering hope for safer environments in radiation-prone situations. Anti-Radiation Drugs Market Insights In 2023, North America dominated the anti-radiation drugs market, primarily due to several factors contributing to growth. These include a substantial patient population afflicted with various illnesses like cancer, increasing numbers of diagnostic procedures, and governmental initiatives aimed at public health in the region. This trend is expected to continue from 2024 to 2030. The prevalence of cancer in the United States, for example, drives a significant demand for anti-radiation drugs. Statistics from the American Cancer Society projected around 2 million new cancer cases in the United States in 2024, leading to heightened demand for these drugs to support cancer diagnostic procedures. Additionally, the US benefits from a strong focus on clinical research and the presence of leading pharmaceutical companies, further bolstering the market for anti-radiation drugs. Moreover, in 2022, the US Department of Health and Human Services (HHS) allocated USD 290 million for the purchase of Nplate, a drug produced by Amgen USA Inc., intended to treat radiation sickness in the event of a nuclear emergency. This investment reflects ongoing efforts to enhance preparedness for radiological and nuclear emergencies and underscores the commitment to saving lives in such scenarios. To know more about why North America is leading the market growth in the anti-radiation drugs market, get a snapshot of the Anti-Radiation Drugs Market Outlook Anti-Radiation Drugs Market Dynamics The market dynamics of anti-radiation drugs are driven by a complex interplay of factors ranging from technological advancements to geopolitical events and regulatory frameworks. One of the primary drivers is the increasing threat of radiation exposure from various sources such as nuclear accidents, medical procedures, and potential radiological terrorism. This heightened awareness has propelled research and development efforts to create effective anti-radiation drugs that can mitigate the harmful effects of radiation exposure. Moreover, the growing prevalence of cancer and the widespread use of radiation therapy as a treatment modality has further fueled the demand for anti-radiation drugs. As more individuals undergo radiation-based treatments, there is a parallel need for medications that can protect healthy tissues and organs from the damaging effects of ionizing radiation. The competitive landscape of the anti-radiation drugs market is characterized by both established pharmaceutical companies and innovative startups vying for market share. Established players often leverage their resources and expertise to develop and commercialize new anti-radiation drugs, while startups focus on disruptive technologies and novel approaches to address unmet needs in radiation protection. Government initiatives and regulatory frameworks also play a crucial role in shaping the market dynamics of anti-radiation drugs. Regulatory agencies set standards for safety, efficacy, and quality assurance, which impact the development, approval, and commercialization of these medications. Additionally, government investments in research and development, as well as funding for procurement and stockpiling of anti-radiation drugs for emergency preparedness, influence market dynamics. Overall, the anti-radiation drugs market is characterized by a dynamic landscape driven by technological innovation, healthcare trends, regulatory factors, and geopolitical considerations. As the threat of radiation exposure continues to evolve, so too will the demand for effective anti-radiation drugs, driving further growth and innovation in this important sector of the pharmaceutical industry. Get a sneak peek at the anti-radiation drugs market dynamics @ Anti-Radiation Drugs Market Dynamics Analysis Anti-Radiation Drugs Market Assessment Anti-Radiation Drugs Market Segmentation Anti-Radiation Drugs Market Segmentation By Compound: Potassium Iodide, Prussian Blue, Diethylenetriamine Pentaacetic Acid, Colony Stimulating Factors, and Others Anti-Radiation Drugs Market Segmentation By Indication: Acute Radiation Syndrome, Cancer Treatment, and Others Anti-Radiation Drugs Market Segmentation By Radiation Type: Ionizing Radiations and Non-Ionizing Radiations Anti-Radiation Drugs Market Segmentation By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others Anti-Radiation Drugs Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the anti-radiation drugs market are set to emerge as the trendsetter explore @ Anti-Radiation Drugs Companies Table of Contents Interested in knowing the anti-radiation drugs market by 2030? Click to get a snapshot of the Anti-Radiation Drugs Market Trends Related Reports Cancer Biomarkers Market Cancer Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer biomarkers companies, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, BD, Merck Millipore, Agilent Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc., Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens Healthineers, Exact Sciences, R&D Systems, Inc., BioVision, Inc., among others. Cancer Therapy Market Cancer Therapy Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer therapy companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd., among others. Oncology Drugs Market Oncology Drugs Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key oncology drugs companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz International GmbH, BeiGene, among others. Liquid Biopsy in Cancer Diagnostics Market Liquid Biopsy in Cancer Diagnostics Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key liquid biopsy in cancer diagnostics companies, including Myriad Genetics Inc., Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health, Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

放射疗法

2024-01-22

·Medical Design and Outsourcing

Potential bioelectric applications of organic mixed ionic–electronic conductors

Researchers in Korea say they found a way to potentially accelerate the development of high-performance organic electrochemical transistor devices with tunable transient responses. Organic mixed ionic-electronic conductors (OMIECs) offer potential bioelectric applications. Researchers at the Gwangju Institute of Science and Technology (GIST) used the transistors as platforms for testing the molecular orientation and ion injection directionality-dependent transient properties of OMIECs. Potential applications for OMIECs include computing and bio-fuel cells in addition to bioelectronics. The researchers say that, to ensure a wider acceptance of these materials, there remains a need to diversify their properties and develop techniques for application-specific OMIEC tailoring. They cite a “severe” lack of research on the molecular orientation-dependent transient behaviors of such conductors. The team at GIST, consisting of researchers from both Korea and the UK, set out to bridge the gap in understanding there. Professor Myung-Han Yoon from the GIST School of Materials Science and Engineering led the researchers. They explored the transient behaviors of OMIECs governed by variations in molecular orientation with the help of an organic electrochemical transistor (OECT). “OECTs are known to mimic the computing mechanisms of neurons and synapses in spiking neural networks (SNNs) and are thus considered promising,” said Yoon. “To aid the growing interest in exploring the dynamic behaviors of OECTs at the frequency domain, we focused on an aspect that is often overlooked. We decided to investigate the correlation between backbone planarity-dependent molecular orientation and transient OECT characteristics.” First, they synthesized two new 1,4-dithienylphenylene (DTP)-based OMEICs, DTP-2T and DTP-P, with co-monomer units, 2,2’-bithiophene and phenylene, respectively. According to GIST, the polymers comprised the same ionic and electronic properties. However, by manipulating the polymer backbone planarity, the researchers controlled the dominant molecular orientation of the mixed conductor system. This polymer then successfully helped to fabricate OECT devices. The team found that the polymers showed similar electrochemical properties despite having different molecular orientations. They then changed the ion injection direction when observing a certain current/voltage during the analysis. In the analysis, the researchers saw that ion injection relative to the molecular orientation affected the length of the ion drift pathway. This, in turn, resulted in peculiar transient responses in OECT devices. The team believes it could use its research to facilitate the design and development of advanced organic mixed conductor materials for biomolecular and biosignal sensors. “OECT-based SNN architectures are anticipated to replace current computing systems in the future by increasing computation speed and reducing energy consumption,” Yoon said. “Our findings are expected to facilitate the realization of SNN-based computing systems soon.”

2023-10-20

·蒲公英Ouryao

药典委：八个化药、九个中药药品标准公示

来源：国家药典委编辑：wangxinglai20042023年10月20日，国家药典委发布了药品标准修订公示，涉及八个化药品种（其中化学制剂药品5个、化学原料药3个）、九个中药品种（其中中药制剂2个、中药材及饮片7个），除参玉补气酒公示期为1个月外、其余品种公示期全部为3个月。一、化学药品： 01 米格列奈钙胶囊我委拟制定米格列奈钙胶囊国家药品标准。为确保标准的科学性、合理性和适用性，现将拟制定的米格列奈钙胶囊国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：程奇蕾电话：010-67079557通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 02 米格列奈钙片我委拟制定米格列奈钙片国家药品标准。为确保标准的科学性、合理性和适用性，现将拟制定的米格列奈钙片国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：程奇蕾电话：010-67079557通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 03 米格列奈钙我委拟制定米格列奈钙国家药品标准。为确保标准的科学性、合理性和适用性，现将拟制定的米格列奈钙国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：程奇蕾电话：010-67079557通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 04 锝[99mTc]喷替酸盐注射液我委拟修订锝[99mTc]喷替酸盐注射液国家药品标准，标准编号：《中国药典》2020年版二部。为确保标准的科学性、合理性和适用性，现将拟修订的锝[99mTc]喷替酸盐注射液国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：程奇蕾电话：010-67079557通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 05 奥扎格雷钠我委拟修订奥扎格雷钠国家药品标准，标准编号：中国药典2020年版二部。为确保标准的科学性、合理性和适用性，现将拟修订的奥扎格雷钠国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：岳志华电话：010-67079576通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 06 注射用奥扎格雷钠我委拟修订注射用奥扎格雷钠国家药品标准，标准编号：WS1-（X-076）-2002Z。为确保标准的科学性、合理性和适用性，现将拟修订的注射用奥扎格雷钠国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：岳志华电话：010-67079576通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 07 奥扎格雷钠注射液我委拟修订奥扎格雷钠注射液国家药品标准，标准编号：WS1-X-095-2005Z。为确保标准的科学性、合理性和适用性，现将拟修订的奥扎格雷钠注射液国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：岳志华电话：010-67079576通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 08 奥扎格雷我委拟修订奥扎格雷国家药品标准，标准编号：中国药典2020年版二部。为确保标准的科学性、合理性和适用性，现将拟修订的奥扎格雷国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：岳志华电话：010-67079576通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061二、中药品种： 01 调胃丹我委拟修订调胃丹国家药品标准，标准编号：WS3-B-0395-90。为确保标准的科学性、合理性和适用性，现将拟修订的调胃丹国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：赵宇新倪龙电话：010-67079523 67079592通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 03 参玉补气酒我委拟修订参玉补气酒国家药品标准，标准编号：WS-5942（B-0942）-2014Z。为确保标准的科学性、合理性和适用性，现将拟修订的参玉补气酒国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起一个月。请认真研核，若有异议，请及时在线反馈，并附相关说明、实验数据和联系方式。来函需打印后加盖公章，个人来函需打印后本人签名，并邮寄至我委通讯地址。公示期满未回复意见即视为对公示标准草案无异议。联系人：赵宇新倪龙电话：010-67079523 67079592通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 03 石菖蒲我委拟修订石菖蒲国家药品标准，标准编号：《中国药典》2020年版一部。为确保标准的科学性、合理性和适用性，现将拟修订的石菖蒲国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：张鹏，翟为民电话：010-67079539，010-67079536电子邮箱：zhangpeng chp.org.cn通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 04 皂角刺我委拟修订皂角刺国家药品标准，标准编号：《中国药典》2020年版一部。为确保标准的科学性、合理性和适用性，现将拟修订的皂角刺国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：张鹏，翟为民电话：010-67079539，010-67079536电子邮箱：zhangpeng chp.org.cn通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 05 艾叶我委拟修订艾叶国家药品标准，标准编号：《中国药典》2020年版一部。为确保标准的科学性、合理性和适用性，现将拟修订的艾叶国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：张鹏，翟为民电话：010-67079539，010-67079536电子邮箱：zhangpeng chp.org.cn通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 06 鲜竹沥我委拟修订鲜竹沥国家药品标准，标准编号：《中华人民共和国卫生部药品标准》中药材第一册。为确保标准的科学性、合理性和适用性，现将拟修订的鲜竹沥国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：张鹏，翟为民电话：010-67079539，010-67079536电子邮箱：zhangpeng chp.org.cn通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 07 广金钱草我委拟修订广金钱草国家药品标准，《中国药典》2020年版一部。为确保标准的科学性、合理性和适用性，现将拟修订的广金钱草国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：张鹏，翟为民电话：010-67079539，010-67079536电子邮箱：zhangpeng chp.org.cn通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 08 地骨皮我委拟修订地骨皮国家药品标准，《中国药典》2020年版一部。为确保标准的科学性、合理性和适用性，现将拟修订的地骨皮国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：张鹏，翟为民电话：010-67079539，010-67079536电子邮箱：zhangpeng chp.org.cn通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 09 肉桂我委拟修订肉桂国家药品标准，标准编号：《中国药典》2020年版一部。为确保标准的科学性、合理性和适用性，现将拟修订的肉桂国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：张鹏，翟为民电话：010-67079539，010-67079536电子邮箱：zhangpeng chp.org.cn通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061

申请上市

100 项与锝[99mTc]喷替酸盐相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14007

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
诊断试剂	日本	PDRadiopharma, Inc.	1979-05-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床1期	-	University of California San Diego	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ERS2021	N/A	弥漫性硬皮病 KL-6 \| SP-D	58	Tc99m – DTPA aerosols	蓋觸餘壓遞簾糧窪選淵(淵顧獵製築築蓋淵鬱衊) = 憲網憲鑰觸膚齋鹽願獵齋鹽窪範鑰壓繭築膚選 (觸鹽襯鬱餘網夢衊鹽窪, 25.7)	积极	2021-09-05
NCT01982123 (CTgov)	N/A	肺癌	12	SPECT/CT+Technetium Tc-99m DTPA	顧選簾膚簾選構積憲築(簾顧鏇衊選觸鑰醖艱遞) = 衊願積繭顧觸簾範顧膚醖鏇廠夢艱願鬱衊獵壓 (鑰顧夢鑰網夢選範齋網, 網齋餘鬱衊艱構觸廠選 ~ 構壓窪壓廠窪顧顧蓋繭) 更多	-	2018-12-13
AUA2017	N/A	-	699	DIETHYLENE TRIAMINE PENTA-ACETIC ACID (DTPA) (Group 1)	衊顧憲遞鹽遞鑰襯齋願(鏇顧膚選鬱窪夢鬱淵衊) = 壓選窪簾繭淵鹽製齋鏇鑰壓鹹構製積獵齋憲襯 (鹹餘艱鹽網襯窪蓋醖繭 ) 更多	-	2017-04-01
AUA2017	N/A	-	699	DIETHYLENE TRIAMINE PENTA-ACETIC ACID (DTPA) (Group 2)	衊顧憲遞鹽遞鑰襯齋願(鏇顧膚選鬱窪夢鬱淵衊) = 網壓觸鏇觸鹽築糧觸願鑰壓鹹構製積獵齋憲襯 (鹹餘艱鹽網襯窪蓋醖繭 ) 更多	-	2017-04-01
Pubmed \| Clin Chest Med	N/A	肺囊性纤维化	-	DTPA (CF subjects)	製憲衊餘顧廠鹹淵窪夢(構淵願餘鬱願蓋觸觸衊) = 鏇觸夢繭糧壓醖廠鑰遞製憲鹽夢憲願願顧鹹鏇 (繭餘獵簾鹹醖顧餘糧獵 )	-	2010-04-01
Pubmed \| Clin Chest Med	N/A	肺囊性纤维化	-	DTPA (Control subjects)	製憲衊餘顧廠鹹淵窪夢(構淵願餘鬱願蓋觸觸衊) = 鏇膚繭壓繭選簾製築鏇製憲鹽夢憲願願顧鹹鏇 (繭餘獵簾鹹醖顧餘糧獵 )	-	2010-04-01